Chemical Pathology Department located at our South Brisbane campus. The role requires working independently as a sole scientist... knowledge and participation in clinical trials and research as required. About you To be successful in this role...
Chemical Pathology Department located at our South Brisbane campus. The role requires working independently as a sole scientist... knowledge and participation in clinical trials and research as required. About you To be successful in this role...
. About the opportunity The Quality Control Analytical Technology Scientist will develop and coordinate the associated... experimental and documentation activities to ensure timely completion of deliverables. Duties Scientist position...
territory plans, supported by thorough market research and pipeline management. Relationship Building: Establish long-term... programs. We believe that a great salesperson must be part artists, part scientist....
and safety specialists). ● Rigorous in research and understanding of key strategic targets and an ability to tailor... must be part artists, part scientist....
to the Department's teaching and research activities. Medical Scientist: Virology/Serology/Molecular The scientist.... With supervision, contribute to the development, selection and adoption of new techniques and methodologies. Medical Scientist...
The Garvan Institute of Medical Research brings together world leading researchers and clinicians, collaborating... The R&D Lead is responsible for overseeing and executing research and development initiatives across the Platform Hubs...
on a massive scale, driving real change. As our Principal Applied Scientist, you'll be at the heart of this transformation... research and proof of concept to full-scale production, ensuring global impact. Leverage the latest breakthroughs...
and sustainability of Australia's agricultural industry. We are currently seeking a motivated ResearchScientist to work at the... involved in our activities and programs. View our . The opportunity Opportunity to lead and conduct research...
Luke Littler was throwing darts while still in his nappy. On Friday, the teenager could take the final step of a journey that began almost as soon as he could walk. Continue Reading »
The Nifty PSU Bank index concluded the year with a gain of 14.48%. Among the top performers, State Bank of India (SBI) led with a gain of 23%, followed by Indian Bank with a return of 24% Continue Reading »
Several auto stocks that were once soaring have seen their prices plummet by as much as 50% from their 52-week highs. These drops could present unique investment opportunities for savvy investors, but beware the risks. Continue Reading »
Kotak Mahindra Bank's stock has fallen over 4% in a year, contrasting with an 11% rise in Nifty Bank. Despite this, it gained 19% from its 52-week low and is 6% below its all-time high. Analysts are optimistic about its recovery potential in 2025. Continue Reading »
Despite a drop in its global market share to 4.2% in December 2024, India’s stable macroeconomics have kept its equity market buoyant. .The Nifty50 recorded a 9% return for 2024, though its performance in December was weak compared to other Asian markets. Continue Reading »
Kotak Mahindra Bank shares have rallied more than 6% in four sessions. Foreign brokerage firm Citi initiated a positive catalyst watch on Kotak Mahindra Bank shares expecting stability in loan growth and lower compression in net interest margin (NIM) in the third quarter of FY25. Continue Reading »
Stocks to buy: Analysts anticipate volatility influenced by US interest rates and trade policies. A potential 5-10% correction is expected in early 2025, yet stock-specific opportunities arise, including buy ratings for Varun Beverages, Tata Technologies, and Kalpataru Projects International. Continue Reading »
Sigachi Industries stock rose over 2% after CARE Ratings reaffirmed its credit ratings. The company saw a 38.1% increase in Q2FY25 revenue, with a profit after tax jump of 39%. However, the stock remains down 14% over the past year. Continue Reading »
Sebi's investigation into Ketan Parekh uncovered a front-running scheme that generated ₹65.77 crore in unlawful profits. In an interim order, the regulator debarred Parekh and two others from trading and issued show-cause notices to 22 entities involved, allowing them 21 days to respond. Continue Reading »